Crispr Therapeutics is trading 4.41% higher at $59.87, with no clear company-specific catalyst identified for the October 6 move. - The latest listed company news was an October 2 announcement of a planned November presentation of early clinical data on zugo-cel at ACR Convergence. - The broader market is modestly higher, with the S&P 500 up 0.45% and Nasdaq up 0.51%; this may support risk appetite, but evidence does not establish it as the direct driver of the stock move.